GlassScriptPhysician profile
Burton G Shaw, JR.
NPI 1720052889
$2,081.32
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,377 · 2020: $705.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $545.44 | 2019-2020 | |
| Amgen INC. | $318.57 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $152.66 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $151.24 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $120.91 | 2019-2020 | |
| Genentech, INC. | $103.45 | 2020 | |
| Amarin Pharma, INC. | $86.76 | 2019-2020 | |
| Gilead Sciences, INC. | $55.10 | 2019-2020 | |
| Lilly USA, LLC | $54.42 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $49.81 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $43.74 | 2019 | |
| Genentech USA, INC. | $43.32 | 2019 | |
| Glaxosmithkline, LLC. | $41.84 | 2019-2020 | |
| Abbvie INC. | $35.52 | 2019 | |
| Astellas Pharma US INC | $32.26 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $27.15 | 2019 | |
| Circassia INC. | $24.39 | 2019-2020 | |
| Pfizer INC. | $23.28 | 2019 | |
| Allergan, INC. | $22.92 | 2020 | |
| Boston Scientific Corporation | $22.22 | 2019 | |
| Optinose US, INC. | $21.50 | 2019 | |
| Shire North American Group INC | $20.13 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.90 | 2020 | |
| Vivus LLC | $16.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.92 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.47 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.36 | 2019 | |
| Eisai INC. | $10.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Burton Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.